Cargando…

Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study

OBJECTIVE: Rituximab (RTX) and cyclophosphamide (CYC) are effective remission-induction therapies in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, combining these therapies may favor prognosis in patients with a major disease presentation. We conducted a retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ysermans, Renée, Busch, Matthias H., Aendekerk, Joop P., Damoiseaux, Jan G.M.C., van Paassen, Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800337/ https://www.ncbi.nlm.nih.gov/pubmed/36589266 http://dx.doi.org/10.1016/j.jtauto.2022.100178

Ejemplares similares

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis
por: Kemna, Michael J., et al.
Publicado: (2017)

Annexin A1 Is Associated with Adverse Clinical Outcomes in Patients with COVID-19
por: Busch, Matthias H., et al.
Publicado: (2022)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial
por: Maritati, Federica, et al.
Publicado: (2017)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Evaluation of antibodies against human HSP60 in patients with MPO-ANCA associated glomerulonephritis: a cohort study
por: Slot, Marjan C, et al.
Publicado: (2006)

Patients with non-relapsing ANCA-associated vasculitis have increased numbers of circulating IL-10 producing Th17 cells
por: Wilde, B, et al.
Publicado: (2010)

T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?
por: Wilde, Benjamin, et al.
Publicado: (2010)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
por: Thiel, Jens, et al.
Publicado: (2011)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series
por: Caroti, L., et al.
Publicado: (2019)

Spondylitis as a Rare Manifestation of Granulomatosis With Polyangiitis
por: Busch, Matthias H., et al.
Publicado: (2020)

Boon and bane of remission induction with rituximab in ANCA-associated vasculitis: lessons learned from the RAVE-ITN follow-up study
por: Kronbichler, Andreas
Publicado: (2013)

ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial
por: Dirikgil, Ebru, et al.
Publicado: (2022)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Endothelial progenitor cells are differentially impaired in ANCA-associated vasculitis compared to healthy controls
por: Wilde, B., et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
por: Salama, Alan D.
Publicado: (2019)

Delta Neutrophil Index Is Associated with Vasculitis Activity and Risk of Relapse in ANCA-Associated Vasculitis
por: Yoo, Juyoung, et al.
Publicado: (2018)

Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis
por: Floyd, Lauren, et al.
Publicado: (2023)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

Complete remission of coronary vasculitis in Churg–Strauss Syndrome by prednisone and cyclophosphamide
por: Riksen, Niels P., et al.
Publicado: (2010)

Predictors of relapses in ANCA-associated small vessel vasculitis with kidney involvement
por: Iuliana, Andreiana, et al.
Publicado: (2014)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis
por: Xiong, Anji, et al.
Publicado: (2021)

Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan
por: Alvarez, Luis, et al.
Publicado: (2023)

Rituximab for the Treatment of Pediatric Double-Positive Small-Vessel Vasculitis
por: Timmermans, Sjoerd A.M.E.G., et al.
Publicado: (2019)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: A comparative cohort study
por: Speer, Claudius, et al.
Publicado: (2021)

The Co-inhibitor BTLA Is Functional in ANCA-Associated Vasculitis and Suppresses Th17 Cells
por: Werner, Kai, et al.
Publicado: (2019)

ANCA-Associated Vasculitis Clinical Presentation and Clinical Predictors of Relapse in Saudi Arabia
por: Alahmari, Hana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j5jbbj91bjoeqp4jt9o8qffou4